“Adenovirus infections – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenovirus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Adenovirus infections Understanding
Adenovirus infections: Overview Adenoviruses are common viruses that cause a range of illness. They can cause cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis). Most adenovirus infections are mild with few symptoms. While each child may experience symptoms differently, the most common include: Respiratory infections, Intestinal tract infections. Adenoviruses are contagious, which means an individual can pass them on to the other. The type of infection determines how it spreads. A Physical exam is generally carried for the diagnosis of Adenovirus infections. Certain blood tests may be done to evaluate the infection. These include: blood test, stool test, urine test and swab test. Children often get over the illness on their own within a few days. Some infections, like pink eye or pneumonia, can last for a week or more.
"Adenovirus infections - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenovirus infections pipeline landscape is provided which includes the disease overview and Adenovirus infections treatment guidelines. The assessment part of the report embraces, in depth Adenovirus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenovirus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Adenovirus infections R&D. The therapies under development are focused on novel approaches to treat/improve Adenovirus infections.
Adenovirus infections Emerging Drugs Chapters This segment of the Adenovirus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adenovirus infections Emerging Drugs • ALVR105 (Viralym-M): Allovir
Viralym-M is designed to play an important role in providing bridging immunity between conditioning and reconstitution of their immune systems. Viralym-M may substantially reduce or prevent virus-associated morbidity and mortality, and dramatically improve patient outcomes. ALVR105 is being studied in Phase II stage of development.
• Adenovirus-specific T cell therapy: Kuur Therapeutics
CytovirADV is naturally occurring VST cell products for the treatment of adenovirus infection reactivation. Kurr Therapeutics (formerly Cell Medica), in collaboration with the UCL Institute of Child Health and the Great Ormond Street Hospital for Children, is evaluating Phase I/II clinical trials for treatment of adenovirus infections.
Further product details are provided in the report……..
Adenovirus infections: Therapeutic Assessment This segment of the report provides insights about the different Adenovirus infections drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Adenovirus infections
There are approx. 5+ key companies which are developing the therapies for Adenovirus infections. The companies which have their Adenovirus infections drug candidates in the most advanced stage, i.e. Phase II include, Allovir.
This report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Adenovirus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Adenovirus infections: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenovirus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenovirus infections drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Adenovirus infections drugs?
• How many Adenovirus infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adenovirus infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenovirus infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adenovirus infections and their status?
• What are the key designations that have been granted to the emerging drugs?
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Apr 2021
Major players in the polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market are Abbott Laboratories, Agilent Technologies Inc., Biomerieux Sa, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd (Roche Diagnostics), Qiagen N.V., Genmark Diagnostics, Thermo Fisher Scientific Inc., General Electric Company (Ge...
280 pages •
By Prescient & Strategic Intelligence Private Limited
• Mar 2021
Precision Medicine Market Research Report: By Type (Therapeutics, Diagnostics, Personalized Medical Care) - Global Industry Analysis and Growth Forecast to 2030
In July 2019, U.S. president Donald Trump decided to bring down the prices of drugs in the country to make them equal or similar to the international rates....
KEY FINDINGS The Europe oxygenators market is projected to develop with a CAGR of 5.27% over the forecast period of 2021 to 2028. Chief factors such as the surging healthcare expenditure, the increasing need for medical devices, the growing public and private investment in research and development, and the prevalence of...
KEY FINDINGS The global cleanroom consumables market is set to project a CAGR of 9.17% during the forecast period, 2021-2028. The growing need for quality products in the manufacturing industries, strict cleanroom regulations and standards, and thriving healthcare & biotechnology industries, drive market growth. MARKET...
120 pages •
By Infiniti Research Limited
• May 2021
Global Snoring Control Devices Market 2021-2025 The analyst has been monitoring the snoring control devices market and it is poised to grow by $ 323.25 million during 2021-2025, progressing at a CAGR of over 5% during the forecast period. Our report on snoring control devices market provides a holistic analysis, market...
The global smoothies market reached a value of around US$ 14 Billion in 2020. A smoothie refers to a thick beverage which is prepared by blending an assortment of fruits, vegetables and other ingredients including milk, seeds, yogurt, ice-cubes, sweeteners, and nutritional and herbal supplements. It is high in nutrients...
175 pages •
By The Business Research Company
• Jul 2021
Major players in the live cell imaging market are Leica Microsystems, Olympus Corporation, Sigma-Aldrich Corporation, PerkinElmer Inc., GE Healthcare, Carl Zeiss Meditec AG, Becton Dickinson and Company, Molecular Devices LLC, Bruker Corporation, Sartorius AG, Oxford Instruments, BioTek Instruments, Etaluma Inc, and CytoSMART Technologies. The...
KEY FINDINGS The global biosurgery market is forecasted to record a CAGR of 6.32% during the projected period of 2021 to 2028. The market growth is attributed to the rising geriatric population, the incidence of musculoskeletal disorders, technological advancements, and the increasing research and development endeavors. MARKET...
The pen needles market is expected to reach USD 2.2 Billion by 2026 from an estimated USD 1.3 Billion in 2021, at a CAGR of 11.2%. Growth in the market is largely driven by the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries. On the other hand, the preference for alternative modes of drug...
The global hyperspectral imaging systems market exhibited strong growth during 2015-2020. A hyperspectral imaging system can be defined as a technique used to analyze a wide spectrum of light through a spectrometer. The device uses reflected, transferred or emitted light from the object to generate its spectral-based...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.